Lupin arm acquires right to Limbitrol, Bacrocin and 7 other medicines from Bausch Health
Mumbai: Global pharma major, Lupin Limited has announced that the company's wholly-owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica, has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc.
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril, and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson's disease.
"This move reinforces our commitment to making healthcare solutions accessible to all patients," the release stated.
"The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness," said Alexandre Franca, Managing Director, MedQuímica. "This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.